Multi-kinase inhibitor
Elzovantinib for Solid Tumors
This trial is testing a new cancer drug to see if it is safe and effective. The study will first test increasing doses of the drug to see what the safe range is. Then, the study will expand to test the drug's effectiveness against different types of cancer.
Alkylating agents
PLDR + Chemotherapy for Lung Cancer
This trial is a Phase I study testing whether Pulsed Low Dose Radiation (PLDR) can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT) for non-small cell lung cancer or esophageal cancer while maintaining similar efficacy.
PD-1 Inhibitor
Immunotherapy + Chemoradiation for Gastroesophageal Cancer
This trial will test if giving patients anti-PD-1 or anti-PD1/anti LAG-3 before surgery, along with chemoradiation, is safe and improves survival in patients with resectable distal esophageal/gastroesophageal junction cancer.
Radiation
Chemoradiotherapy for Esophageal Cancer
This trial tests if adding certain chemotherapy drugs to radiation therapy can better relieve swallowing difficulties and improve quality of life for patients with advanced esophageal cancer who can't undergo surgery. These drugs are commonly used in treatment for esophageal cancer and have shown promising results in various studies.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
Zolbetuximab + Chemotherapy for Gastric or Gastroesophageal Junction Cancer
This trial will compare the effects of a new drug (zolbetuximab) on cancer progression, safety, and quality of life, compared to the standard treatment (placebo plus CAPOX).
Trials for Gastric Adenocarcinoma Patients
Monoclonal Antibodies
Zolbetuximab + Chemotherapy for Gastric or Gastroesophageal Junction Cancer
This trial will compare the effects of a new drug (zolbetuximab) on cancer progression, safety, and quality of life, compared to the standard treatment (placebo plus CAPOX).
Monoclonal Antibodies
Paclitaxel +/− Cixutumumab for Esophageal Cancer
This trial is testing how well paclitaxel (a chemotherapy drug) works with or without cixutumumab (a protein-blocking drug) to treat patients with esophageal or gastroesophageal junction cancer that has spread to other parts of the body.
Trials for HER2 Positive Patients
PARP Inhibitor
Berzosertib + Irinotecan for Gastric Cancer
This trial tests a combination of berzosertib and irinotecan in patients with advanced gastric or gastroesophageal junction cancer. Berzosertib blocks enzymes needed for cancer growth, and irinotecan kills or stops the spread of cancer cells. Irinotecan has been used in various combinations for treating advanced gastric and gastroesophageal cancers, showing some efficacy but not proving superior to other treatments. The goal is to find a more effective treatment for these difficult-to-treat cancers.
Antibody-Drug Conjugate
T-DXd Combinations for Stomach Cancer
This trial is investigating the safety and preliminary effectiveness of a new cancer drug, trastuzumab deruxtecan (T-DXd), for treating HER2-positive gastric and esophageal cancers. The study will also look at whether T-DXd is more effective when given in combination with other cancer treatments.
Phase 3 Trials
Monoclonal Antibodies
Zolbetuximab + Chemotherapy for Gastric or Gastroesophageal Junction Cancer
This trial will compare the effects of a new drug (zolbetuximab) on cancer progression, safety, and quality of life, compared to the standard treatment (placebo plus CAPOX).
Checkpoint Inhibitor
Nivolumab for Esophageal Cancer
This trial is testing if Nivolumab, a drug that helps the immune system fight cancer, can help cancer patients stay free of the disease longer. Nivolumab has been shown to improve survival in various cancers, including melanoma and esophageal cancer.
Alkylating agents
Chemotherapy + Radiotherapy for Esophageal and Gastric Cancer
This trial is studying how well adding radiotherapy to the usual chemotherapy treatment works compared to the usual treatment alone in treating patients with esophageal and gastric cancer.
Trials With No Placebo
Monoclonal Antibodies
Sacituzumab Govitecan + Capecitabine for Gastrointestinal Cancer
This trial is testing a new combination of drugs, sacituzumab govitecan and capecitabine, for patients with advanced gastrointestinal cancers that have not responded to standard treatments. Researchers
View More Related Trials
Frequently Asked Questions
Introduction to
What are the top hospitals conducting undefined research?
In the quest to conquer various medical conditions, clinical trials play a crucial role in driving innovation and improving patient outcomes. When it comes to pioneering research in an undefined area, several esteemed hospitals across the United States are at the forefront of these efforts. One such institution is M D Anderson Cancer Center located in Houston, where 12 active trials focused on this unidentified condition are currently underway. Not far behind is the Washington University School of Medicine in Saint Louis with eight ongoing undefined trials. These institutions are dedicated to unraveling the mysteries surrounding this enigmatic condition.
Meanwhile, Massachusetts General Hospital in Boston also contributes significantly by conducting six active clinical trials related to this unknown ailment. This hospital has earned its reputation as a leading center for medical advancements and continues its commitment to exploring new frontiers through innovative research protocols.
The Memorial Sloan Kettering Cancer Center in New york stands shoulder-to-shoulder with these institutions, prioritizing investigations into this undefined condition with six active clinical trials taking place within their premises. With their wealth of expertise and resources, they strive to shed light on critical aspects that remain unexplored.
Lastly, we have Moffitt Cancer Center situated in Tampa making notable strides by conducting five ongoing clinical trials aimed at unravelling information about this mysterious condition.
While we await further clarity and understanding regarding this yet-unidentified illness or disorder being studied at these top hospitals offering unprecedented opportunities for advancement; we can appreciate the tireless dedication of researchers working towards breakthroughs that will undoubtedly enhance our knowledge base and ultimately bring us closer to solutions needed for improved healthcare outcomes worldwide
Which are the best cities for undefined clinical trials?
When it comes to undefined clinical trials, several cities stand out as leading hubs for research and innovation. Houston, Texas boasts 29 active trials exploring treatments like Arm A: FLOT-TNT (Investigational Arm), Nivolumab, and Phase 1 elzovantinib. Boston, Massachusetts follows closely behind with 25 ongoing studies focused on Phase 1 elzovantinib, Trastuzumab deruxtecan, and Nivolumab interventions. Los Angeles, California is also a significant player with 22 active trials examining treatments such as Telatinib, DKN-01 300mg, and Cardiac Aggressive Risk MitigAtion Plan. These cities offer individuals access to cutting-edge clinical trials that pave the way for advancements in medical care and potential breakthroughs in treatment options.
Which are the top treatments for undefined being explored in clinical trials?
In the field of undefined treatment research, clinical trials are uncovering promising options. Leading the pack is daratumumab, a drug currently being tested in six active trials. Since its introduction in 2012, it has been involved in 134 breast cancer trials. Belantamab mafodotin follows with four ongoing trials and a total of 26 breast cancer studies since its debut in 2018. Another notable contender is lenalidomide, which has three active clinical trials for breast cancer and an impressive track record of 280 all-time studies since its first listing in 2003. These treatments hold great potential as researchers strive to find effective solutions for patients facing undefined conditions.
What are the most recent clinical trials for undefined?
In the realm of clinical trials, several recent studies have emerged in search of effective treatments for undefined conditions. These trials include the evaluation of Olympus GIF 190 endoscope, a phase 2 study that aims to enhance diagnostic capabilities and improve patient outcomes. Additionally, CA-4948 is undergoing a phase 1 trial to assess its potential as a therapeutic option for this enigmatic condition. Another promising avenue being explored involves treatment approaches such as gastrectomy with HIPEC (hyperthermic intraperitoneal chemotherapy) in a phase 2 trial. Furthermore, the combination therapy of tadalafil and chemotherapy is being investigated in another phase 2 study, showing promise for patients with undefined conditions. Lastly, Enterotracker is currently in a phase 1 trial, offering hope for improved diagnostics and understanding within this challenging field.
What undefined clinical trials were recently completed?
Recently completed clinical trials that were not specified include a range of diverse studies across various medical fields. These trials, while unspecified in detail, represent the tireless efforts of researchers and participants to advance medical knowledge and improve patient care. Though specific information is lacking, these completed trials contribute to the collective body of evidence and pave the way for future discoveries and breakthroughs.